THE INVENTION RELATES TO A FORMULA (I), IN WHICH R IS A HYDROGEN OR HALOGEN ATOM OR A (C1-C6) ALKYL GROUP； X IS ONE OR MORE SUBSTITUENTS SELECTED FROM A HYDROGEN OR HALOGEN ATOM, A (C1-C6)ALKYL, HALO(C1-C6)ALKYL, (C1-C6)ALKOXY, HALO(C1-C6)ALKOXY, CYANO, HYDROXY, OR HYDROXY(C1-C6)ALKYL GROUP； Y IS A HYDROGEN OR HALOGEN ATOM OR A (C1-C6)ALKYL GROUP； R1 IS AN NR2R3 OR OR4 GROUP； R2 AND R3 INDEPENDENTLY ARE A HYDROGEN ATOM, A (C1-C6)ALKYL, HYDROXY(C1-C6)ALKYL OR OXO(C1-C6)ALKYL GROUP, OR R2 AND R3, TOGETHER WITH THE NITROGEN ATOM SUPPORTING THE SAME, FORM A HETEROCYCLE OPTIONALLY SUBSTITUTED BY A (C1-C6)ALKYL, HYDROXY, OR OXO GROUP； AND R4 IS A (C1-C6)ALKYL, HYDROXY(C1-C6)ALKYL, OR OXO(C1-C6)ALKYL GROUP, IN THE BASE OR ACID ADDITION SALT STATE. SAID FORMULA CAN BE USED THERAPEUTICALLY FOR TREATING OR PREVENTING DISEASES LINKED TO THE NUCLEAR RECEPTORS NURR-1, ALSO KNOWN AS NR4A2, NOT, TINUR, RNR-1, AND HZF3
